Lunsekimig
Based on 1 Customer Validation
Lunsekimig (SAR443765) is a nanobody composed of 5 VH domains that targets both TSLP and IL-13. Lunsekimig blocks the functional effects of TSLP and IL-13, inhibits related inflammatory signals, and improves lung function associated with type 2 inflammation. Lunsekimig can be used in research on asthma and type 2 inflammation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.00%
- CAS. Nr.: 2770858-49-4
- Molecular Weight:69.702 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P99397
SonelokimabAnti-IL-17A/F Antibody -
HY-P99796
OzoralizumabAnti-TNFα Antibody -
HY-P99638
GefurulimabAnti-C5/albumin Dual Antibody -
HY-P99366A
Tezepelumab (anti-TSLP)Anti-TSLP Antibody -
HY-P99115
EnvafolimabAnti PD-L1 Antibody -
HY-P99227
Caplacizumab (His Tag)Anti-VWF Nanobody -
HY-P99025
LebrikizumabIL-13 Inhibitor -
HY-P991162
TilrekimigAnti-IL-3/IL-13/TSLP Monoclonal Antibody -
HY-P99947
RimteravimabBivalent VHH-Fc Antibody -
HY-P99550
TozorakimabInterleukin-33 Inhibitor -
HY-P99673
ItepekimabIL-33 mAb -
HY-P99053
TralokinumabIL-13 Inhibitor
Biologische Aktivität
Beschreibung
Isotype
VH-VH-VH-VH-VH
Species Reactivity
Human
IC50 & Target
[1]|
IL-13 |
TSLP |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
VH-VH-VH-VH-VH
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded IL-13 Protein, Human (HEK293, His, HY-P70568) on NTA biosensor, can bind Lunsekimig with an affinity constant of 2.806E-09 M as determined in BLI assay. -
Loaded Serum Albumin/ALB Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78077) on NTA biosensor, can bind Lunsekimig with an affinity constant of 5.297E-08 M as determined in BLI assay. -
Loaded TSLP Protein, Human (HEK293, His, HY-P70818) on HIS1K biosensor, can bind Lunsekimig with an affinity constant of <1.0E-11 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 2770858-49-4
-
Appearance Liquid
-
Molecular Weight 69.702 kDa
-
Color Colorless to light yellow
-
Synonyms
SAR443765
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Deiteren A, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science. 2024 Jun;17(6):e13864. [Content Brief]
[2]. Deiteren A, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. The European respiratory journal. 2025 Apr;65(4):2401461. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Lunsekimig Related Classifications
HY-P990748 Related Classifications
Powered by Bioz